Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Nonresectable primary and metastatic liver tumors are common malignancies that lack therapies allowing substantial prolongation of survival. Recent progress in molecular and cell biology has opened the way to novel therapies based on biological modifiers, gene transfer, and autologous stem cells. It is now possible to transfer therapeutic genes to the tumor or pericancerous tissue, and to control their expression for long periods of time. It is also feasible to generate autologous endothelial progenitor cells that can be recruited by tumoral vessels acting as vehicles to convey therapeutic genes to the interior of the tumor mass. Combination of biological modifiers, gene therapy, and cell therapy will hopefully provide efficient means to combat inoperable neoplasms in a not-very-distant future.

Original publication

DOI

10.1016/s0039-6109(03)00230-5

Type

Journal article

Journal

The Surgical clinics of North America

Publication Date

04/2004

Volume

84

Pages

673 - 696

Addresses

Division of Hepatology and Gene Therapy, Fundación para la Investigación Médica Aplicada (FIMA), University of Navarra, Avenida Pio XII s/n, 31080 Pamplona, Spain. jprieto@unav.es

Keywords

Liver, Dendritic Cells, Animals, Humans, Adenoviridae, Liver Neoplasms, Neovascularization, Pathologic, Interferon-alpha, Cancer Vaccines, Immunologic Factors, Immunotherapy, Adoptive, Genetic Vectors, Genetic Therapy